China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
This article was originally published in PharmAsia News
The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.
You may also be interested in...
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.